01Identity
Device and system
Laser source, wavelength, pulse domain, spot delivery, cooling and protective equipment identify the platform.
Pigment Laser · Device-Based Treatment · Istanbul
Pigment Laser · Device-Based Treatment · Istanbul
Pigment Laser
Pigment diagnosis and exclusion of malignancy come before laser selection; not every pigmentation concern is an appropriate laser target. The name of an energy class does not identify a treatment protocol: the exact device, applicator, tissue path, labelled use and clinical aim must be considered together.
Online information cannot select a device, settings, treatment depth, anatomical path or number of sessions. Final suitability requires an in-person medical examination.
Device Identity
System · energy · preparation · route
A device category is not a complete clinical description.
Four separate identifiers keep unlike systems and unlike tissue effects from being treated as equivalent.
02Mechanism
Energy source
A selected wavelength is absorbed by a target pigment; pulse structure influences how energy is confined in tissue.
03Traceability
Preparation and consumables
Clinical and dermoscopic assessment precedes device preparation; eye protection and laser safety controls are mandatory.
04Tissue path
Invasiveness and route
Optical energy enters the lesion from the surface; pigment depth and surrounding skin determine exposure and risk.
Target and Boundary
Target tissue · clinical aim · realistic limits
The tissue question comes before the machine name.
The lesion diagnosis, pigment type, depth, change over time and skin phototype come before device choice.
What a review may establish
- Identify a defined tissue target after examination
- Compare the exact device label with the proposed use
- Set a measurable and limited clinical endpoint
- Keep alternatives and a no-treatment option open
What must not be assumed
- Guarantee regeneration, collagen production, tightening or lifting
- Treat all devices with one marketing name as equivalent
- Predict duration or a fixed session count
- Replace diagnosis, surgery or disease-directed care when these take priority
A device label does not authorise treatment of every brown lesion; regional indication and lesion type must match.
Medical Suitability
Diagnosis and anatomy before device selection
Five checks precede any personal energy plan.
The examination separates the clinical finding, tissue depth, healing risk, device status and proportionate alternatives.
- 01
Confirm the diagnosis
Symptoms, onset, examination and any need for dermoscopic, imaging or specialist assessment come first.
- 02
Map tissue and anatomy
The lesion diagnosis, pigment type, depth, change over time and skin phototype come before device choice.
- 03
Review healing and exposure
An undiagnosed, changing or suspicious lesion, melasma instability, recent tanning, impaired healing or high pigment risk may preclude treatment.
- 04
Verify the exact system
A device label does not authorise treatment of every brown lesion; regional indication and lesion type must match.
- 05
Define follow-up
A baseline, expected reaction, adverse-effect route and stopping criteria are agreed. Do not treat a diagnostically uncertain lesion; stop and reassess unexpected bleeding, ulceration, severe pain, blistering or persistent change.
Device and Treatment Path
Traceability without a public settings recipe
Preparation, delivery and aftercare form one auditable chain.
Clinical and dermoscopic assessment precedes device preparation; eye protection and laser safety controls are mandatory.
01Before
Verify device and patient
Identity, manufacturer instructions, labelled use, maintenance, consumables and patient-specific exclusions are checked.
- Record the exact system
- Confirm consumable integrity
- Complete safety checks
02During
Control the tissue path
Optical energy enters the lesion from the surface; pigment depth and surrounding skin determine exposure and risk.
- Protect vulnerable structures
- Monitor tissue response
- Stop if safety limits are crossed
03After
Connect observation to follow-up
Do not treat a diagnostically uncertain lesion; stop and reassess unexpected bleeding, ulceration, severe pain, blistering or persistent change.
- Document the treated region
- Explain expected reactions
- Provide an escalation route
Public information does not provide wavelength, depth, fluence, power, pulse, pass, cartridge, transducer or anatomical treatment settings.
Evidence and Limits
Device-, indication- and endpoint-specific
Evidence for one system cannot be generalised to an entire marketing class.
Evidence is strongest for selected benign diagnosed lesions and specific systems, not pigmentation as a single category.
Keep the device exact
Applicator design, energy delivery, feedback and tissue control may differ between systems.
Keep the indication exact
Evidence in one diagnosis, body area or skin type does not establish another use.
Read endpoints carefully
Short-term appearance scores, photographs, symptoms and histology are not interchangeable outcomes.
Retain uncertainty
Comparative effectiveness, durability and uncommon harms may remain uncertain.
Manufacturer information may identify a product and its instructions, but it is not treated as independent evidence of a general class effect.
Individual Plan
One device · one target · one review point
A proportionate plan includes a reason not to proceed.
Selection follows diagnosis, device identity, labelled context, tissue target, risk and realistic alternatives.
Name the target
The lesion diagnosis, pigment type, depth, change over time and skin phototype come before device choice.
Name the system
Laser source, wavelength, pulse domain, spot delivery, cooling and protective equipment identify the platform.
Name the endpoint
Record what change would be clinically meaningful and when it can reasonably be reviewed.
Name the exit
Do not treat a diagnostically uncertain lesion; stop and reassess unexpected bleeding, ulceration, severe pain, blistering or persistent change.
Course and Follow-Up
Expected reaction · adverse effect · stopping
Reassessment is part of the treatment, not an afterthought.
The follow-up pathway distinguishes an expected short response from a complication or an absent clinical reason to repeat.
- 01Same day
Immediate review
Comfort, skin response and any unexpected neurological, vascular or thermal sign are checked.
- 02Early
Early healing
Pain, swelling, blistering, crusting, discharge, colour change or asymmetry are reviewed as relevant.
- 03Later
Clinical endpoint
Comparable records assess the agreed target without attributing every change to the device.
- 04Decision
Continue, change or stop
Do not treat a diagnostically uncertain lesion; stop and reassess unexpected bleeding, ulceration, severe pain, blistering or persistent change.
Risks and Alternatives
Energy, tissue path and anatomy shape harm
Serious and delayed adverse effects remain visible.
Post-inflammatory hyperpigmentation, hypopigmentation, burn, scar, textural change and delayed diagnosis of malignancy are material risks.
01
Expected reactions
Temporary pain, redness, swelling, tenderness or surface change may occur depending on the system and route.
02Safety
Complications
Post-inflammatory hyperpigmentation, hypopigmentation, burn, scar, textural change and delayed diagnosis of malignancy are material risks.
03Options
Alternatives
Diagnostic observation, biopsy or specialist referral, photoprotection, topical care, peel, other device assessment or no treatment
04Decision
Withhold or stop
Treatment is withheld or stopped when the indication, consent, safety controls or follow-up cannot support a proportionate plan.
Treatment is withheld when diagnosis, device status, anatomy, consent or follow-up is inadequate. Do not treat a diagnostically uncertain lesion; stop and reassess unexpected bleeding, ulceration, severe pain, blistering or persistent change.
Istanbul and Follow-Up
Assessment and safety must travel together
International care requires a workable review route.
Travel planning does not shorten observation or remove the need for local medical access.
01Before travel
Organise the question
History and comparable photographs prepare discussion without confirming a device.
02In Istanbul
Examine in person
Diagnosis, anatomy, device, label, risks and alternatives are reviewed together.
03Treatment day
Keep exact records
System, consumable, treated region and observations remain traceable.
04After return
Plan escalation
Do not treat a diagnostically uncertain lesion; stop and reassess unexpected bleeding, ulceration, severe pain, blistering or persistent change.
The Doctor Aslan Approach
Device-specific, anatomy-led and evidence-bounded
The machine follows the medical decision.
Doctor Aslan separates device identity, energy path, tissue target, authorisation and evidence before discussing a personal plan.
Diagnose first
Do not use an energy label as a substitute for a clinical diagnosis.
Audit the system
Verify manufacturer, model, applicator, consumable, maintenance and labelled use.
Protect anatomy
Match invasiveness and energy path to vulnerable structures and healing risk.
Accept no treatment
Withholding treatment remains appropriate when expected benefit or safety is insufficient.
Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information about Pigment Laser; no personal settings or outcome guarantee
Frequently Asked Questions
Short and clear
Questions commonly asked before a decision.
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
01What is Pigment Laser?+
Pigment Laser is described on this page as one defined clinical route. Its role, limits and possible alternatives are considered together rather than treating the method name as a personal recommendation.
02Who may be assessed for Pigment Laser?+
Suitability depends on the medical question, history, examination, the exact product or device where relevant, realistic aims and an individual benefit–risk assessment.
03What remains undecided after an online review?+
Diagnosis, definitive suitability, the treatment protocol, product, dose or device settings, expected response and the option not to proceed remain subject to personal medical assessment.
04How are treatment and follow-up in Istanbul planned?+
The in-person examination remains the decision point. Expected early reactions, warning signs, the direct contact route, return travel and access to appropriate local medical care are discussed before treatment.
Next Step
Define the finding · identify the system · compare alternatives